Approval · Notice of Compliance 23085 · 2020
FLEXERIL: Notice of Compliance 23085
Issued January 7, 2020
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 23085
- Date
- January 7, 2020
- Company
- Orimed Pharma Inc.Boucherville, Quebec, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Abbreviated New Drug Submission (ANDS)
- Submission class
- Labelling Only
- Reason
- New labelling and administrative licensing agreement between two companies
- Canadian reference product
- PMS-CYCLOBENZAPRINE (Pharmascience Inc.)
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| FLEXERIL | 02495422 | Dormant |
Medicinal ingredients
- CYCLOBENZAPRINE HYDROCHLORIDE 10 MG per TAB